Aquestive Therapeutics, Inc. (NASDAQ:AQST) is highlighted as one of the 7 Oversold Pharma Stocks to Buy Now. Lake Street Capital Markets adjusted AQST’s valuation model due to an expected approval delay, lowering the price target to $6 from $8. The company plans to resubmit its application for Anaphylm in the third quarter after receiving a Complete Response Letter.

Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced it will present new clinical results for Anaphylm at the 2026 AAAAI Annual Meeting. These results will showcase Anaphylm as a non-invasive alternative to injectable epinephrine for treating severe allergic reactions, including anaphylaxis. AQST focuses on developing and commercializing orally administered and film-based drug delivery therapies.

Although AQST shows investment potential, there are AI stocks with greater upside and lower downside risk. Investors seeking undervalued AI stocks with growth potential should consider alternative options. For more insights on short-term AI stocks, refer to the provided link for a free report. Disclosure: None.

Read more at Yahoo Finance: Lake Street Adjusts Aquestive Therapeutics, Inc. (AQST) Valuation Model on Expected Approval Delay